A reduction in prostate-specific antigen (PSA) screening in men aged 40 years and older was associated with an increase in metastatic prostate cancer diagnoses in the United States, according to results of a study presented at the 2021 ASCO Genitourinary Cancers Symposium.
Between 2008 and 2016, across all states, the mean percentage of men undergoing PSA screening decreased from 61.8% to 50.5%, while the mean incidence of metastatic prostate cancer at diagnosis increased from 6.4 to 9.0 per 100,000 (adjusted P<0.001 for both) (abstract 228).